瑞士罗氏公司周二表示,将以高达15亿美元的现金收购美国生物制药公司Poseida Therapeutics。此次收购交易的价格为每股9美元,如果达到特定里程碑,股东还将获得每股最高4美元的不可交易或有价值权,使交易价值达到约15亿美元。交易预计将于2025年第一季度完成。
Poseida及其员工将加入罗氏,成为这家瑞士公司制药部门的一部分。
罗氏表示,此次收购将为该公司在同种异体细胞治疗领域赋能,重点关注Poseida与罗氏在血液系统恶性肿瘤领域现有合作涵盖的CAR-T项目。
截至发稿,Poseida夜盘大涨超17%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.